52y.o.1 dose; 2doses (2-6monthsapart) ifimmunocomp40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factor75y.o.Tyrer-Cuzickmodeltamoxifenanxietydiabetes50y.o.≥6.5%40y.o.HepatitisCovariancancerbreastcancerdepression3%≥20%raloxifeneq5yoverweight/ obesity40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factorHIVcommunity-dwelling,postmenopausalwomen≥ 126mg/dLcardiovasculardiseasecervicalcancer40-59 y.o.,ASCVD ≥10%, lowbleeding risk40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorsdementiaFractureRiskAssessmentTool65y.o.tobaccouseq1y≥ 100mg/dL2 doses,2-6monthsapart< 60y.o.40-70 y.o.,ASCVD ≥10%, lowbleeding riskq2ymultidoseinitial series,then 1 doseat 2-6monthspneumococcalq15ystatin≥5.7%≥ 200mg/dLlungcancerq3yaromataseinhibitorsq1-2ymammogrambased on lifeexpectancy /health statusaspirinwomenage 55-64 y.o.herpeszosterGailmodelhormonetherapy60y.o.Timedup andgo testhypertensionq1ymammograminsufficientevidenceforscreening≤q2y≥ 140mg/dLPREVENTequationHepatitisBdyslipidemiacolorectalcancer≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactors52y.o.1 dose; 2doses (2-6monthsapart) ifimmunocomp40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factor75y.o.Tyrer-Cuzickmodeltamoxifenanxietydiabetes50y.o.≥6.5%40y.o.HepatitisCovariancancerbreastcancerdepression3%≥20%raloxifeneq5yoverweight/ obesity40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factorHIVcommunity-dwelling,postmenopausalwomen≥ 126mg/dLcardiovasculardiseasecervicalcancer40-59 y.o.,ASCVD ≥10%, lowbleeding risk40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorsdementiaFractureRiskAssessmentTool65y.o.tobaccouseq1y≥ 100mg/dL2 doses,2-6monthsapart< 60y.o.40-70 y.o.,ASCVD ≥10%, lowbleeding riskq2ymultidoseinitial series,then 1 doseat 2-6monthspneumococcalq15ystatin≥5.7%≥ 200mg/dLlungcancerq3yaromataseinhibitorsq1-2ymammogrambased on lifeexpectancy /health statusaspirinwomenage 55-64 y.o.herpeszosterGailmodelhormonetherapy60y.o.Timedup andgo testhypertensionq1ymammograminsufficientevidenceforscreening≤q2y≥ 140mg/dLPREVENTequationHepatitisBdyslipidemiacolorectalcancer≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactors

Untitled Bingo - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
  1. 52 y.o.
  2. 1 dose; 2 doses (2-6 months apart) if immunocomp
  3. 40-75 y.o., ASCVD ≥ 7.5%, ≥ 1 risk factor
  4. 75 y.o.
  5. Tyrer-Cuzick model
  6. tamoxifen
  7. anxiety
  8. diabetes
  9. 50 y.o.
  10. ≥ 6.5%
  11. 40 y.o.
  12. Hepatitis C
  13. ovarian cancer
  14. breast cancer
  15. depression
  16. 3%
  17. ≥20%
  18. raloxifene
  19. q5y
  20. overweight / obesity
  21. 40-75 y.o.; LDL > 190 or ASCVD ≥ 10% + ≥ 1 risk factor
  22. HIV
  23. community-dwelling, postmenopausal women
  24. ≥ 126 mg/dL
  25. cardiovascular disease
  26. cervical cancer
  27. 40-59 y.o., ASCVD ≥ 10%, low bleeding risk
  28. 40-75 y.o., LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  29. dementia
  30. Fracture Risk Assessment Tool
  31. 65 y.o.
  32. tobacco use
  33. q1y
  34. ≥ 100 mg/dL
  35. 2 doses, 2-6 months apart
  36. < 60 y.o.
  37. 40-70 y.o., ASCVD ≥ 10%, low bleeding risk
  38. q2y
  39. multidose initial series, then 1 dose at 2-6 months
  40. pneumococcal
  41. q15y
  42. statin
  43. ≥ 5.7%
  44. ≥ 200 mg/dL
  45. lung cancer
  46. q3y
  47. aromatase inhibitors
  48. q1-2y mammogram based on life expectancy / health status
  49. aspirin
  50. women age 55-64 y.o.
  51. herpes zoster
  52. Gail model
  53. hormone therapy
  54. 60 y.o.
  55. Timed up and go test
  56. hypertension
  57. q1y mammogram
  58. insufficient evidence for screening
  59. ≤ q2y
  60. ≥ 140 mg/dL
  61. PREVENT equation
  62. Hepatitis B
  63. dyslipidemia
  64. colorectal cancer
  65. ≥ 40 y.o.; LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors